Enrollment complete in Aradigm's inhaled ciprofloxacin Phase 2b study in non-cystic fibrosis bronchiectasis
Links shared publicly online about this topic.
- 419total visits
Enrollment complete in Aradigm's inhaled ciprofloxacin Phase 2b study in non-cystic fibrosis bronchiectasis
Aradigm Corporation announced the last patient was enrolled in a Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (CFI, ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE), a severe progressive respiratory disease for which there is currently no approved treatment in the U.S.
View full resource at news-medical.net
Tags: Bronchiectasis, Disease and Condition, Antibiotic, Cipro, Ciprobay, disease
Most Recently Shared on March 23, 2011 at 4:49 am By:
Enrollment complete in Aradigm's inhaled ciprofloxacin Phase 2b study in non-cystic fibrosis bronchiectasis: Ara... http://bit.ly/hMkIse
Advertisement
